High rate of tumor shrinkage amongst pancreatic cancer patients: study

Adding cisplatin to the standard gemcitabine/nab-paclitaxel drug treatment provided a very high rate of tumor shrinkage for individuals with advanced pancreatic cancer, according to the results of a pilot clinical demo conducted by the HonorHealth Research Start and the Translational Genomics Research Start (TGen). Related Posts:Radioimmunotherapy, Gemcitabine combination shows early…Tucatinib (ONT-380) progressing in pivotal demo against…Fox Chase trial tests promising therapy in early breast…New nanopharmaceutical may help overcome resistance to…The antibody that normalizes tumor vesselsThe post High rate of tumor shrinkage amongst pancreatic cancer patients: study appeared first on My Irritable Bowel Syndrome Story.
Source: My Irritable Bowel Syndrome Story - Category: Gastroenterology Authors: Tags: IBS News Source Type: blogs